Monograph Details
|
|
Cardiovascular System
> CHF and arrhythmias
|
|
NATRECOR |
| Manufacturer |
|
Scios, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Vasodilator (human B-type natriuretic peptide). |
| Generic Name |
|
Nesiritide 1.5 mg/vial; pwd for IV inj after reconstitution and dilution; contains mannitol. |
| Indications |
|
Acutely decompensated CHF with dyspnea at rest or with minimal activity. |
| Children |
|
Not recommended. |
| Adults |
|
2 micrograms/kg IV bolus once, then 0.01 microgram/kg per minute by continuous IV infusion; limited experience with therapy >48 hours. Doses up to 0.03 micrograms/kg per minute have been used; see literature. Reduce dose or discontinue if symptomatic hypotension occurs. |
| Contraindications |
|
Systolic BP <90mmHg. Not for primary treatment of cardiogenic shock. Not recommended for intermittent outpatient infusion, or scheduled repetitive use, or to improve renal function or enhance diuresis. |
| Precautions |
|
Not recommended in significant valvular stenosis, restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, other conditions where vasodilators are inappropriate, or when cardiac output is dependent on venous return, or in patients with low cardiac filling pressures. Impaired renal function (esp if severe heart failure). Monitor BP closely. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Hypotension potentiated by oral ACE inhibitors. |
| Adverse Reactions |
|
Hypotension, headache, GI upset, dizziness, angina, insomnia, AV node conduction abnormalities, azotemia. |
| How Supplied |
|
Single-use vials—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
